AU2001287930A1 - Pharmaceutical formulation for pulmonary or nasal administration - Google Patents
Pharmaceutical formulation for pulmonary or nasal administrationInfo
- Publication number
- AU2001287930A1 AU2001287930A1 AU2001287930A AU8793001A AU2001287930A1 AU 2001287930 A1 AU2001287930 A1 AU 2001287930A1 AU 2001287930 A AU2001287930 A AU 2001287930A AU 8793001 A AU8793001 A AU 8793001A AU 2001287930 A1 AU2001287930 A1 AU 2001287930A1
- Authority
- AU
- Australia
- Prior art keywords
- pulmonary
- pharmaceutical formulation
- nasal administration
- nasal
- administration
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Abandoned
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/007—Pulmonary tract; Aromatherapy
- A61K9/0073—Sprays or powders for inhalation; Aerolised or nebulised preparations generated by other means than thermal energy
- A61K9/0078—Sprays or powders for inhalation; Aerolised or nebulised preparations generated by other means than thermal energy for inhalation via a nebulizer such as a jet nebulizer, ultrasonic nebulizer, e.g. in the form of aqueous drug solutions or dispersions
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
- A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
- A61K9/1605—Excipients; Inactive ingredients
- A61K9/1629—Organic macromolecular compounds
- A61K9/1641—Organic macromolecular compounds obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyethylene glycol, poloxamers
- A61K9/1647—Polyesters, e.g. poly(lactide-co-glycolide)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
- A61K9/141—Intimate drug-carrier mixtures characterised by the carrier, e.g. ordered mixtures, adsorbates, solid solutions, eutectica, co-dried, co-solubilised, co-kneaded, co-milled, co-ground products, co-precipitates, co-evaporates, co-extrudates, co-melts; Drug nanoparticles with adsorbed surface modifiers
- A61K9/145—Intimate drug-carrier mixtures characterised by the carrier, e.g. ordered mixtures, adsorbates, solid solutions, eutectica, co-dried, co-solubilised, co-kneaded, co-milled, co-ground products, co-precipitates, co-evaporates, co-extrudates, co-melts; Drug nanoparticles with adsorbed surface modifiers with organic compounds
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| GB0024271A GB0024271D0 (en) | 2000-09-25 | 2000-09-25 | Improved methods and compositions for pulmonary delivery of actives |
| GB0024271.9 | 2000-09-25 | ||
| PCT/GB2001/004255 WO2002024175A2 (en) | 2000-09-25 | 2001-09-25 | Pharmaceutical formulation for pulmonary or nasal administration |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| AU2001287930A1 true AU2001287930A1 (en) | 2002-04-02 |
Family
ID=9900645
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| AU2001287930A Abandoned AU2001287930A1 (en) | 2000-09-25 | 2001-09-25 | Pharmaceutical formulation for pulmonary or nasal administration |
Country Status (3)
| Country | Link |
|---|---|
| AU (1) | AU2001287930A1 (en) |
| GB (1) | GB0024271D0 (en) |
| WO (1) | WO2002024175A2 (en) |
Families Citing this family (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2008102563A1 (en) * | 2007-02-23 | 2008-08-28 | Next21 K.K. | Therapeutic or prophylactic agent for vasoconstriction |
Family Cites Families (6)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP0257915B1 (en) * | 1986-08-11 | 1993-03-10 | Innovata Biomed Limited | Pharmaceutical formulations comprising microcapsules |
| EP0655237A1 (en) * | 1993-11-27 | 1995-05-31 | Hoechst Aktiengesellschaft | Medicinal aerosol formulation |
| WO1996025918A1 (en) * | 1995-02-24 | 1996-08-29 | Nanosystems L.L.C. | Aerosols containing nanoparticle dispersions |
| US6428771B1 (en) * | 1995-05-15 | 2002-08-06 | Pharmaceutical Discovery Corporation | Method for drug delivery to the pulmonary system |
| ZA9711732B (en) * | 1996-12-31 | 1998-12-28 | Quadrant Holdings Cambridge | Methods and compositions for improvement bioavailability of bioactive agents for mucosal delivery |
| GB9705588D0 (en) * | 1997-03-18 | 1997-05-07 | Anglia Research Foundation | Stable particle in liquid formulations |
-
2000
- 2000-09-25 GB GB0024271A patent/GB0024271D0/en not_active Ceased
-
2001
- 2001-09-25 WO PCT/GB2001/004255 patent/WO2002024175A2/en active Application Filing
- 2001-09-25 AU AU2001287930A patent/AU2001287930A1/en not_active Abandoned
Also Published As
| Publication number | Publication date |
|---|---|
| WO2002024175A3 (en) | 2003-09-12 |
| GB0024271D0 (en) | 2000-11-15 |
| WO2002024175A2 (en) | 2002-03-28 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| AU2002222118A1 (en) | Pharmaceutical compositions for inhalation | |
| AU2001226029A1 (en) | Pharmaceutical formulation and method for pulmonary and oral delivery | |
| AU2002239282A1 (en) | Pharmaceutical formulations comprising paclitaxel, derivatives, and pharmaceutically acceptable salts thereof | |
| AU2001266338A1 (en) | Pharmaceutical compositions for angiogenic therapy | |
| AU2002257582A1 (en) | Pharmaceutical formulation | |
| AU4328800A (en) | Pharmaceutical formulation | |
| AU2001284444A1 (en) | Preparations for oral administration | |
| AU6715600A (en) | Pharmaceutical formulations | |
| AU2001292331A1 (en) | 5-amidino-2-hydroxybenzenesulfonamide derivatives, pharmaceutical compositions containing the same and intermediates for their preparation | |
| AU2001292331A2 (en) | 5-amidino-2-hydroxybenzenesulfonamide derivatives, pharmaceutical compositions containing the same and intermediates for their preparation | |
| AU2001232017A1 (en) | Pharmaceutical composition for pulmonary delivery | |
| AU3201701A (en) | Pharmaceutical composition for pulmonary delivery | |
| AU2001258550A1 (en) | Insulin formulation for inhalation | |
| AU2003238039A1 (en) | Nasal peptide pharmaceutical formulation | |
| AU2002215114A1 (en) | Pharmaceutical compositions for inhalation | |
| AU4977300A (en) | Pharmaceutical formulations | |
| AU3055099A (en) | A pharmaceutical formulation for nasal administration | |
| AU1141101A (en) | Pharmaceutical aerosol formulations comprising s-salmeterol | |
| AU5072000A (en) | Pharmaceutical composition for nasally administering water-soluble active substances | |
| AU5415699A (en) | Water-soluble pharmaceutical formulation for administering sildenafil | |
| AU2001287930A1 (en) | Pharmaceutical formulation for pulmonary or nasal administration | |
| AU4884701A (en) | Malonanilic acid derivatives, medicinal compositions containing the same and usethereof | |
| AU2001274236A1 (en) | Dry-powder pharmaceutical formulation for inhalation comprising alpha4-intergrinantagonist | |
| AU1388501A (en) | Pharmaceutical formulation | |
| AU2001228784A1 (en) | Inositol derivatives and their pharmaceutical use |